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Abstract
Objective To examine the costs and cost effectiveness of telehealth in
addition to standard support and treatment, compared with standard
support and treatment.
Design Economic evaluation nested in a pragmatic, cluster randomised
controlled trial.
SettingCommunity based telehealth intervention in three local authority
areas in England.
Participants 3230 people with a long term condition (heart failure,
chronic obstructive pulmonary disease, or diabetes) were recruited into
the Whole Systems Demonstrator telehealth trial between May 2008
and December 2009. Of participants taking part in the Whole Systems
Demonstrator telehealth questionnaire study examining acceptability,
effectiveness, and cost effectiveness, 845 were randomised to telehealth
and 728 to usual care.
Interventions Intervention participants received a package of telehealth
equipment and monitoring services for 12 months, in addition to the
standard health and social care services available in their area. Controls
received usual health and social care.
Main outcome measure Primary outcome for the cost effectiveness
analysis was incremental cost per quality adjusted life year (QALY)
gained.
Results We undertook net benefit analyses of costs and outcomes for
965 patients (534 receiving telehealth; 431 usual care). The adjusted
mean difference in QALY gain between groups at 12 months was 0.012.
Total health and social care costs (including direct costs of the
intervention) for the three months before 12 month interview were £1390
(€1610; $2150) and £1596 for the usual care and telehealth groups,
respectively. Cost effectiveness acceptability curves were generated to
examine decision uncertainty in the analysis surrounding the value of
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the cost effectiveness threshold. The incremental cost per QALY of
telehealth when added to usual care was £92 000. With this amount,
the probability of cost effectiveness was low (11% at willingness to pay
threshold of £30 000; >50% only if the threshold exceeded about £90
000). In sensitivity analyses, telehealth costs remained slightly
(non-significantly) higher than usual care costs, even after assuming
that equipment prices fell by 80% or telehealth services operated at
maximum capacity. However, the most optimistic scenario (combining
reduced equipment prices with maximum operating capacity) eliminated
this group difference (cost effectiveness ratio £12 000 per QALY).
Conclusions The QALY gain by patients using telehealth in addition to
usual care was similar to that by patients receiving usual care only, and
total costs associated with the telehealth intervention were higher.
Telehealth does not seem to be a cost effective addition to standard
support and treatment.
Trial registration ISRCTN43002091.
Introduction
Management of people with long term conditions is under the
spotlight, given the rapidly growing prevalence of such
conditions in ageing populations. Treatment costs for people
with long term conditions make up 69% of all spending on
health and social care in England, and the number of people
with at least one long term condition could rise by three million
to 18 million by 2025.1 Among other factors, the rising financial
impact of such conditions has been linked to increases in the
lifetime prevalence of diabetes2 and other chronic diseases such
as chronic obstructive pulmonary disease3 and congestive heart
failure.4
There are compelling arguments for tackling long term
conditions to improve quality of life, while being mindful of
the need to contain costs.5 In particular, there is considerable
interest in the potential of technologies such as telehealth to
generate cost effectiveness gains and even to yield cost savings6
while maintaining or improving patient outcomes.6 7
Evidence on the effectiveness of telehealth is accumulating;
systematic reviewers have judged it as promising for managing
respiratory and cardiac disease and diabetes,8-11 despite study
limitations such as small sample sizes and poor designs.
Evidence of the effect of telehealth on service use, costs, or cost
effectiveness remains scarce12-16 Furthermore, most studies have
been conducted in the United States, leaving open the question
of their relevance in the United Kingdom.14
The term “telehealth” encompasses both “telemonitoring” and
telephone support. With telemonitoring, patients transmit data
on their vital signs for real time monitoring, for instance, via
video link or by store and forward systems (where data are
submitted by the patient and transmitted to the health
professional for later assessment).8 12 With telephone support,
healthcare providers provide support to patients or carers via
the standard telephone system. Telephone support can also
involve monitoring of vital signs data as reported by patients.8 9
In practice, telehealth can be a hybrid of these approaches. We
compared the costs and cost effectiveness of telehealth services
(as an addition to standard support and treatment) with those of
standard support and treatment alone. This analysis was part of
the Whole System Demonstrator (WSD) programme, funded
by the Department of Health.7 17
Methods
WSD telehealth trial
A pragmatic, cluster randomised controlled trial (the WSD
telehealth trial) used routinely collected administrative datasets
to examine the effect of telehealth on primary and secondary
healthcare and social care use by individuals with long term
conditions (chronic obstructive pulmonary disease, heart failure,
or diabetes) in three demographically diverse sites.18 The WSD
sites (local authority areas in England) were chosen for having
an established record of joint working between health and social
care; they were covered by four primary care trusts.
Randomisation took place at the general practice level. All
practices within the four primary care trusts were eligible to
participate. Aminimisation procedure was devised to randomise
practices to usual care or to a telehealth intervention in addition
to standard care, to achieve a balance across trial arms of
selected practice characteristics that were potentially associated
with trial outcomes. These characteristics included site; practice
size; index of multiple deprivation 2007 (IMD)19; proportion of
white or non-white patients; and prevalence of diabetes, heart
failure, and chronic obstructive pulmonary disease.
The patients at participating practices were eligible for study
inclusion if they were 18 years or older, with at least one of
three long term index conditions (chronic obstructive pulmonary
disease, heart failure, or diabetes). Index conditions were
confirmed by primary or secondary care medical records, the
Quality Outcomes Framework register, or a local clinician.
Patients who met diagnostic criteria but had cognitive
impairments that would have prevented them from using the
telehealth equipment independently could be recruited into the
trial, provided that they had a carer who could assist them in
using telehealth as prescribed in the context of the trial. We
excluded non-English speaking patients from the trial, because
the telehealth equipment provided information and instructions
only in English.20
All patients that appeared to meet the study criteria, based on a
review of practice records and input from local healthcare
professionals, were invited to participate in the main trial.
Patients who consented to sharing health and social care data
with the research team were visited by the local WSD project
team to confirm the patient’s eligibility and check the suitability
of the patient’s home for telehealth. Eligible patients were
presented with verbal and written information about the trial,
and if they were willing to participate in the trial, were asked
to provide informed written consent. The main telehealth trial
recruited 3230 participants from 179 general practices between
May 2008 and December 2009. Patients in the control group
received usual health and social care for the 12month follow-up
period, and were then offered telehealth subject to a further
clinical assessment. Patients in the intervention group received
telehealth in addition to the standard health or social care
services available in their area.20
WSD questionnaire study
The WSD telehealth questionnaire study was nested within the
parent trial described above. The questionnaire study used
participant reported outcomes collected from a subset (n=1573)
of the parent trial sample and served as the basis for evaluating
acceptability, effectiveness, and cost effectiveness of telehealth
as a supplement to standard care.18 20 Patients who had cognitive
impairments that would impair their ability to independently
complete evaluation instruments were not eligible for the
questionnaire study, although they were eligible for the parent
trial, because data for outcome measures were to be collected
first hand.20
All eligible patients were asked during the assessment visit by
the WSD project team whether they would be willing to
participate in the questionnaire study in addition to the main
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trial. Baseline interviews were arranged with those trial
participants who agreed, and recruitment into the questionnaire
study continued with the aim of reaching the 550 participants
for each index condition (or 1650 in total).20
At baseline, patients agreeing to participate were visited by
trained interviewers18 who obtained additional informed written
consent for the questionnaire study, and collected information
on primary and secondary outcomes. Data for service use were
also collected using the Client Services Receipt Inventory.21
This instrument collects comprehensive information on patient
service use, living arrangements, and employment status as well
as patterns of unpaid care and support by their family or other
carers. The Client Services Receipt Inventory and other study
instruments were posted to participants at four and 12 months
after randomisation. Patients who had not returned their
questionnaire at 12 months were contacted to arrange an
interview (563 (57%) questionnaires were subsequently
completed by telephone or by interview face to face).We report
here on data from the WSD telehealth questionnaire study.
Context
Telehealth was defined within the trial as “the remote exchange
of data between a patient and healthcare professional to assist
in the diagnosis and management of a healthcare condition.”18
Participants used telemonitoring equipment to collect and
transmit vital signs data. These data were classified into risk
related alerts (for example, using a traffic light system),
according to parameters that would be set initially on the basis
of clinical guidelines or by a clinician responsible for the
patient’s care. These parameters were reset by a clinician
(general practitioner, telehealth nurse, or community matron)
as required, after an initial settling-in period. The exact response
to the alert depended on the risk level associated with the
readings, clinical judgment, and local protocols that were usually
based on clinical guidelines.18
Monitoring staff were also able to transmit health related
questions, messages, or videos to educate patients on their
conditions, using the telehealth base unit or set top box. Patients
in the telehealth group were not charged for using the telehealth
services (for instance, freephone numbers were provided for
calls to central monitoring teams, or for transmitting vital signs
data). But these patients were expected to have or to arrange
for a telephone line, power points, and electricity; patients at
one site were expected to have a television available.
The telehealth systems thus included both telemonitoring and
telephone support. The trial was not designed to investigate the
effect of individual service configurations or technologies.18
Rather, we sought to understand whether “telehealth,” as a class
of technologies added to standard support and treatment, is cost
effective compared with standard care alone. However, each
study site had different suppliers and service models, which
evolved over the course of the trial.
Telehealth equipment included a base unit (freestanding or a
television set top box) and peripherals such as weigh scales,
pulse oximeters, blood pressure cuff, and glucometers. The
peripherals could communicate with the base unit either
wirelessly or by cable. To set the costing methods and issues
in context, the web appendix provides a brief overview of the
service models used in 2009-10.
Costs of delivering telehealth interventions
We calculated the per person costs to purchasers of the telehealth
equipment and support provided within the trial.
Telehealth equipment
Information on each participant’s telehealth equipment was
obtained from sites, along with prices paid. In two sites, a stock
of equipment was purchased in advance of the trial. If equipment
was purchased rather than rented, costs of base units were
annuitised over five years, and costs of peripherals annuitised
either over the lifetime of the item (if information was available
from sites or manufacturers’ specifications) or over five years.
Five years has been used as the standard lifetime for both
computer technology and “short life medical and other
equipment” in NHS (the UK’s health service) capital
accounting.22 This same duration has been used in other
telemedicine studies.23 We raised prices to 2009 levels by using
the Hospital and Community Health Services’ prices inflator.24
Site 3 provided information on the monthly rental charges for
four different combinations of peripherals and on the cost of
pulse oximeters and glucometers purchased separately.
Telehealth support costs
Telehealth support costs included personnel involved in
monitoring and responding to telehealth “triggers,” supervision
of monitoring staff, back office functions, project management
(planning, contract supervision, monitoring), and staff training.
Cost estimates excluded posts (or parts thereof) associated purely
with trial recruitment or evaluation support. From each site, we
obtained the information needed to calculate overheads on
directly provided staffing costs, including on-costs and indirect
administrative and premises costs. If projects were unable to
quantify indirect administrative overheads, these were estimated
as 16% of direct salary costs.24 Costs relating to technology
support (for example, for accommodating delivery personnel)
were calculated by following costs methods used by the Personal
Social Services Research Unit for capital overheads.24
Costs of central telehealth monitoring teams, whether directly
provided or contracted out, were calculated top down, dividing
total expenditure by the annual number of service users. We
carried out top down costing because of the variety of
interventions and rapid changes in deliverymodels that occurred
in response to the trial timetable. By contrast, costs of
contributions by “local” telemonitoring staff in two sites were
calculated bottom up. In site 1, data provided by the sites was
used to estimate that 15% of trial participants were monitored
by community matrons and specialist nurses; and that in site 2,
24% were monitored by community matrons and specialist
nurses.
Much of the work by local monitoring personnel involved direct
patient contact for reasons not necessarily associated with
telemonitoring. This contact, whether response related or not,
might be observed and reported by questionnaire participants.
To avoid double counting, only the time spent by local personnel
in monitoring the telehealth screen and in training on how to
use the telemonitoring systemwas costed. The average duration
of local monitoring time per patient day (2 min) was provided
by sites’ project teams, and used to calculate the total time spent
per year, to which we attached relevant unit costs.
We calculated local staff costs from information provided by
project teams on numbers of staff and their pay bands,25 using
band midpoints. On-costs and nationally applicable overheads
(capital, indirect, and direct) were added.24 Total monitoring
costs from both central and local teams were combined and
divided by the total number of participants monitored in the
year, providing an average monitoring cost per participant per
year.
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The costs of installers and engineers (at sites 1 and 2) or the
contract cost for installation and maintenance (at site 3) were
split into fixed and variable components.We divided these costs
by applying proportions calculated from detailed information
provided by one site on the expenditure breakdown (2009-10)
on activities related to installation, de-installation, and
maintenance. This analysis suggested that 90% of costs related
to installers (and their associated administrative and capital
overheads, plus costs of equipment support in terms of transport
and storage) are fixed and spread over five years. The remaining
10% was considered to be incurred during that year only
(2009-10). Calculations also included expenditure associated
with software licences, maintaining servers, and freephone
telephone numbers, and arrangements for transmitting data from
the telehealth base units.
We combined the average costs per person of central and local
monitoring, installation, and maintenance (including
administrative, premises, and capital overheads), to calculate
the cost of telehealth support per intervention participant per
site. This cost of telehealth “implementation” therefore varied
between sites, and was added to the individually varying
equipment costs. A small number of participants randomised
to the control group but who had received telehealth equipment
were also allocated direct intervention costs.
Self reported service use data
We applied national unit costs (2009-10 prices) from published
sources to self reported data on service use (table 1⇓).
Information for most unit costs for community health and social
care was taken from the Personal Social Services Research
Unit24; national reference costs were applied to hospital based
services.26 All costs associated with self reported service use
collected for the three months before 12 month follow-up were
multiplied by four to give a yearly equivalent for the cost
effectiveness analysis. Costs included were assumed to be
incurred by health and social care agencies even if patients
contributed copayments (such as for dentistry, chiropody, and
optician services). For equipment and adaptations, only costs
to public organisations were included, and we excluded costs
reported as incurred by the patients or their families.
Service use and costs are reported as means and standard errors,
unless otherwise stated. Where descriptive statistics are
presented, differences are given as raw differences (£) between
group means and as standardised differences (the difference
between group means, divided by the standard deviation of the
total sample,33 presented in percentage terms)
Outcome measures
The primary outcome for the cost effectiveness analysis was
the incremental cost per quality adjusted life year (QALY)
gained, constructing utility values from the EQ-5D34 with
societal weights (the York A1 tariff).35 36 We calculated QALYs
by using an area under the curve analysis, with linear
interpolation of utility scores between baseline and 12 month
assessments.37
The secondary outcome was ICECAP-O,38 a capability index
for older people that measures quality of life along five
dimensions: attachment, security, role, enjoyment, and control.
Attribute levels were valued for people aged 65 years and over
(1=full capability, 0=no capability).
We explored two other outcomes. The short form of the
Spielberger State-Trait Anxiety Inventory (Brief STAI)39
measures “state anxiety” and has been widely used, including
for people with diabetes.40 The measure was rescaled in our
analysis to a 0-1 range of possible levels of anxiety (0=lowest,
1=highest; original score range 6-24). The short form Center
for Epidemiologic Studies Depression scale (CESD-10)41 is a
screening instrument for depression symptoms. The scale ranges
from 0 to 30; a difference of five points or more has been
interpreted as clinically meaningful (that is, showing depressed
symptoms).42 All outcome measures described were assessed
at baseline, at short term follow-up (four months), and long term
follow-up (12 months).
Statistical analysis
The economic evaluation adopted a health and social services
perspective. Analyses were carried out in Stata version 11.43
The cost effectiveness analysis was based on the estimation of
net benefit regressions.44-46 We constructed a model of net
monetary benefit that was suitable for clustered data, to explore
the probability that telehealth is a cost effective addition to
standard care. This probability was calculated across a range of
assumed values for decision making in health and social care,
based on willingness to pay for an incremental outcome gain.
The models adjusted for baseline costs, baseline utility,37 or
baseline secondary outcome measure; and for site, age, sex,
ethnicity, IMD score (including the proportion of trial patients
who scored in each fifth of the IMD score range, (indicated as
IMD groups 1-5)),19 and two indicators of health need (one
constructed from a range of chronic conditions sourced from
acute hospital records,47 and the index condition).18
Net monetary benefit was defined as (ΔE)×λ−ΔC (where
ΔE=additional (or incremental) outcome associated with the
telehealth intervention, ΔC=additional cost of telehealth, and
λ=willingness to pay per unit of outcome gain). The net benefit
approach allows costs and outcomes to be considered on the
same monetary scale; net benefit regressions take account of
sampling uncertainty and adjust for the covariates noted above.46
Using results from the net benefit regressions, we estimated
incremental cost effectiveness ratios (ICERs)—that is, the
additional cost per unit of outcome from the addition of
telehealth to standard care. We also plotted cost effectiveness
acceptability curves, depicting the likelihood that telehealth is
cost effective given different assumptions about willingness to
pay for outcomes.
ICERswere estimated by finding the level of willingness to pay
where net monetary benefit equals zero, at which point the
probability of cost effectiveness becomes 50%.45 39 The slope
of the line for net monetary benefit, as a function of willingness
to pay thresholds, estimated the difference in effect between
groups.45 46 Telehealth should be interpreted as cost effective if
the ICER is below some maximum level of willingness to pay
for a unit of outcome (or if it is associated with both reduced
costs and improved outcomes). In the analysis, willingness to
pay values ranged from £0 to £95 000 (€110 000; $144 000)
per QALY. These values included the range associated with
National Institute for Health and Clinical Excellence (NICE)
recommendations for using health technologies in the NHS
(willingness to pay £20 000 to £30 000 per QALY).48 49
We used methods that reflected the cluster randomised nature
of the trial, to avoid bias in the standard errors of regression
coefficients.50 51 A multilevel approach was taken, investigating
population averaged models of cost and effect. Generalised
estimating equations models 52 53 were fitted using Stata
command xtgee, with the general practice as cluster identifier.
Models specified a log link, assuming a gamma distribution and
an equal or exchangeable correlation structure, and included
semi-robust standard errors. We defined incremental net
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monetary benefit as the difference between groups or the average
marginal effect of the intervention, estimated using the
“margins” command.
Missing data
Missing data for costs and outcome were imputed using the
multiple imputation function in SPSS version 19. Because not
all participants completed every item in the Client Services
Receipt Inventory, we imputed costs by categories (table 2⇓).
Multiple imputation models included predictors from the
outcome measures at all time points, including measures of
health related quality of life (EQ-5D) and well being
(ICECAP-O), psychosocial measures (measures of depression,
anxiety, self efficacy), sociodemographic variables from the
analysis (age, sex, site, IMD, ethnicity), and trial related
variables (treatment allocation, reasons for withdrawal from the
trial, and costs at baseline or at 12 month follow-up (in the
categories given in table 2).
Five participants who completed the outcome measures but did
not complete any questions on service use were dropped from
the analyses. We did multiple imputation of missing
observations by sampling from an identified subset of data
having similar values to the unit with missing data, to create 10
complete datasets. These data were first analysed and then
combined to produce unbiased results.54 55 The analysis adhered
to the intention to treat principle, with participants grouped
according to their randomised allocation, although a few patients
in the intervention group received usual care and some controls
received telehealth.
Sensitivity analyses—decreases in the costs of
equipment
Equipment costs might have a considerable effect on the overall
costs of telehealth, and conclusions about cost effectiveness
could depend on the unit cost of equipment use. Equipment
prices may fall over time as technology evolves. We explored
the effect of falling input prices, using data we obtained from
the Department of Health on equipment prices in North
American markets in 2010. We applied general price decreases
of 50% and 80% to equipment costs calculated for the trial.
Because North American equipment prices were 10-50% of the
price for equipment purchased in England before the trial, these
assumptions were relatively conservative.
Sensitivity analyses—“at capacity” scenario
Telehealth teamsmay have been able to work at higher capacity.
We initially planned to monitor about 1000 patients per site for
a few months during the trial, as those in the intervention group
were gradually joined by those in the control group. However,
teams were monitoring about half to three fifths of this original
target in 2009-10. Sensitivity analyses explored the costs of a
service that monitored 1000 people in each site, on the
assumption that central teams would not have had to increase
staff complement to cope with additional demand, and that
service structure and patient outcomes would not have changed
at this larger scale (table 3⇓).
The two parameters—equipment costs and telehealth support
costs—were varied as has been described and entered into the
statistical analyses, using the same models and covariates as in
the main analysis.
Results
Of 3230 participants in the WSD telehealth trial, 1573
participated in the WSD telehealth questionnaire study: 845
were randomised to the telehealth intervention and 728 to usual
care.20 Seventeen people who were randomised to usual care
received telehealth, and six randomised to telehealth did not
receive any equipment. At baseline, data for service use were
available for 841 intervention participants and 728 usual care
participants. At 12 month follow-up, outcomes data were
available for 974 participants, of whom 969 had costs data
available (538 intervention, 431 control; table 1). Costs data at
baseline and 12 month follow-up were available for 965
participants (534 intervention, 431 control).
By 12 month follow-up, 599 (38%) participants had dropped
out of the questionnaire study. Baseline characteristics were
grouped by participantswith available economic data at baseline,
those who completed the study instruments at 12 months, and
those who did not complete the 12 month questionnaires (table
4⇓). In terms of these characteristics, the groups were broadly
similar at the outset of the trial, although there was a
significantly larger proportion of people with heart failure in
the usual care group than in the telehealth group (38% v 31%;
z=2.6894, P=0.0072). The telehealth group also had a larger
proportion of patients with chronic obstructive pulmonary
disease than the usual care group (40% v 34%; z=−2.5087,
P=0.012).
There were also differences between intervention and usual care
participants in relation to the IMD groups 1 and 2 (that is, the
two least deprived groups)19 (table 4), but mean scores did not
differ substantially. Within each treatment group, the baseline
and follow-up samples were broadly similar in age, number of
comorbidities, health and social care costs, the proportion of
women, and proportions of patients with chronic obstructive
pulmonary disease and heart failure.
There were statistically significant differences between the
baseline and follow-up telehealth samples in terms of mean
IMD score, the proportion of patients within IMD group 5 (that
is, the most deprived group), and the proportion of patients with
an index condition of diabetes (table 4). The balance of long
term conditions in the intervention group thus shifted somewhat
over time, but at both baseline and follow-up, participants with
chronic obstructive pulmonary disease made up the largest
group; in the control group, participants with heart failure made
up the largest group. The proportion of participants in the sample
from IMD group 5 was significantly lower at follow-up than at
baseline (15% v 20%; z=2.34, P<0.05; table 4). This difference
between follow-up and baseline was also reflected in the mean
IMD scores in the intervention group (26.1 v 27.7; P=0.046;
table 4). The control group had no significant differences
between characteristics at baseline and at follow-up completion.
Service use and costs
Service use was summarised under broad categories (table 1).
Individual items of service use were not imputed, thus mean
values (not adjusted for case mix) were presented for
non-missing cases. Reported use of most services was broadly
similar between the telehealth and usual care groups, although
the standardised difference between groups for emergency
department services exceeded 10%. There was a broad pattern
of slightly fewer reported contacts with services for the
telehealth group than for the usual care group.
Table 3 lists the annual telehealth intervention delivery and
equipment unit costs, and intervention unit costs excluding those
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costs relating to project management. There was considerable
variation across sites, partly because of differences in the extent
of contracting out, project management structures, and lead
partner. Based on these unit costs, the average annual cost per
participant for telehealth equipment and support was estimated
as £1847 (standard error £11.3), for participants who had
received equipment and for whom costs data were available at
12 month follow-up.
Table 2 presents costs of self reported service use over the last
three months before 12 month follow-up, by category; mean
values summarise the costs derived from the imputation process.
Excluding the direct costs of the intervention, hospital costs
made up about half the total costs for all participants, followed
by primary care costs (about 18%); combined costs of social
care, day care, and equipment (about 16%); and drugs about
(18%). Excluding intervention specific costs, costs in the
telehealth group were lower than those in the usual care group,
with a standardised difference in costs of about 12% between
groups. If direct intervention costs were included, costs in the
telehealth group were higher than in the usual care group
(standardised difference of 10%). For the intervention group,
the three month costs for direct equipment averaged £169 per
person, and other direct costs of telehealth were £289 per
person—representing 18% and 11%, respectively (table 2).
Total costs for health and social care, for the last three months
before the 12 month interview, were £1139 and £1380 for the
telehealth and usual care groups, respectively, excluding the
direct costs of the intervention; if direct costs were included,
these costs were £1596 and £1390, respectively.
Cost effectiveness
Table 5⇓ shows costs and outcomes data from the net benefit
analyses, as well as corresponding raw mean values for base
case costs and outcomes (n=965). The difference between
treatment groups in rawmean QALYwas small. In the adjusted
net benefit model, we saw little difference between the groups
in this primary outcome at 12month follow-up (mean difference
0.012) or in ICECAP-O (0.012). On the CESD-10 and Brief
STAI adjusted mean scores, the telehealth group scored slightly
higher than the usual care group (0.128 and 0.042, respectively;
table 5). Costs including intervention costs were higher among
the telehealth group than the usual care group.
Analyses for net benefit regression showed an ICER of £92 000
per QALY (table 5). Excluding project management costs, the
ratio fell to £79 000. For other outcome measures, the ICER for
an improvement from no capability to full capability on the
ICECAP-O scale was £98 000. The ratio for an improvement
from highest to lowest levels of anxiety on the Brief STAI scale
was £27 000; for the CESD-10 scale, the ICER was £9000 for
achieving a five point reduction.
Whether telehealth is considered to be cost effective will depend
on the willingness to pay for the outcomes generated. Figure
1⇓ presents the probability that telehealth would be seen as cost
effective as an addition to usual care, using an acceptability
curve for different values of willingness to pay. At the £30 000
threshold (associated with NICE recommendations41), the
probability of cost effectiveness was 11%. Figure 1 also shows
the probability of cost effectiveness if costs related to project
management were excluded: at the £30 000 threshold, the
probability of cost effectiveness was 17%. Indeed, this
probability including management costs only exceeded 50% at
threshold values of willingness to pay above £90 000. Excluding
project management costs, the probability exceeded 50% only
at values above about £79 000.
In relation to an improvement from no capability to full
capability on the ICECAP-O index, telehealth would not be cost
effective at values of willingness to pay below £95 000 (fig 2⇓).
Although there were larger differences between intervention
and control groups in state anxiety and depression symptoms,
they were difficult to interpret. The probability of cost
effectiveness for a 100% improvement from highest to lowest
levels of anxiety on the Brief STAI only exceeded 50% at
willingness to pay levels above about £27 000 (fig 3⇓). The
probability that the treatment was cost effective in achieving a
five point reduction on the CESD-10 scale exceeded 50% at
levels of willingness to pay above about £9000, and reached
90% at about £30 000 (fig 4⇓).
Sensitivity analyses
Reductions in equipment costs: full utilisation
Equipment costs contributed a sizeable proportion of direct
costs per person for the telehealth group (table 2). Table 2 also
presents the three month costs estimated for the net benefit
sensitivity analyses (multiplied by four here to give the yearly
equivalent). If equipment prices fell by 80%, estimated mean
costs per year (unadjusted) for the telehealth group fell from
£6384 (standard error £355) to £5845 (£354). However, total
costs of the telehealth group remained slightly higher than those
of the usual care group (difference £299, standardised difference
4%). If equipment prices decreased by 50%, total costs for the
telehealth group were also higher than for the usual care group
(£496, 6%). Under the 80% reduction in equipment costs
scenario, the ICER fell to £52 000 per QALY (table 5). In the
scenariowhere the servicewas working “at capacity,” the annual
mean costs of the telehealth group fell to £5909 (standard error
£354).
Reduction in equipment costs and full utilisation
(combined scenario)
The two sensitivity analyses were also combined. At an 80%
reduction in equipment costs and a reduction of support costs
associated with working at higher capacity, the difference
between groups decreased. Total mean costs of telehealth per
year (unadjusted) per participant were £166 (standardised mean
difference −2%) less for telehealth (at £5370 (standard error
£354)) than for usual care (three month costs are shown in table
2). At a 50% reduction in equipment costs with the same
decreased labour costs, the corresponding cost was £31 less
(−0.40%) for the telehealth group (at £5572 (£354)) than for
the usual care group (table 2). However, in the adjusted model
of costs derived from the net benefit regression analyses (table
5), the costs remained higher for the telehealth group than for
the usual care group, assuming 80% and 50% reductions in
input price and higher working capacity (increases of £109 and
£308, respectively).
With an 80% reduction in equipment costs and operating at the
higher capacity, the cost effectiveness ratio fell to £12 000 per
QALY. Figure 5⇓ shows cost effectiveness acceptability curves
for all sensitivity analyses. No substantial changes to the results
were seen: assuming an 80% reduction in equipment costs, the
probability that telehealth was cost effective was 34% at a
willingness to pay level of £30 000 per QALY. Results from
the sensitivity analyses based on operating at increased capacity
were similar. However, combining the two scenarios increased
the likelihood that telehealth was cost effective, to 61% for a
willingness to pay of £30 000 per QALY.
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Discussion
TheWSD telehealth trial was the largest pragmatic, randomised
controlled trial of telehealth in England, with cost and outcome
data at 12 months for 969 participants. Costs of self reported
service use, combined with telehealth intervention costs, were
greater for the group randomised to telehealth in addition to
standard care than for the group randomised to usual care alone.
In a model adjusting for demographic characteristics and level
of need, this difference in costs was considerably (although not
significantly) greater if project management costs were taken
into consideration. For the primary outcome measure, the
probability that telehealth was cost effective was relatively low,
only exceeding 50% at willingness to pay values above £90
000. On the secondary outcome measures of anxiety and
depression symptoms, the probability of cost effectiveness rose
above 50% at willingness to pay values in excess of £27 000
and £9000, respectively.
Strengths and limitations
A limitation of self report data on service use is that respondents
may have under-reported, particularly if they are frequent users
of a service.56 57 However, self reporting remains the only way
to collect data for a wide range of health and social care services,
since administrative data are agency or service specific and not
always reliable. It has been recommended that a shorter period
of recall is used for frequently used services,56 and in this study,
we used a three month timeframe. We assumed that costs
between nine and 12 months could be multiplied up to a yearly
cost. This estimation made our cost effectiveness findings
conservative; longitudinal hospital data have shown that initial
differences between groups in bed days narrowed over the period
of the intervention.47 However, the pattern associated with acute
hospital services cannot be assumed to hold with services that
are more frequently used and less episodic, such as community
nursing or home care.
The extent to which the costs and outcomes differed between
those participants who completed the 12 month follow-up and
those who did not is not known. By adjusting for demographic
and cost covariates at baseline that might influence the decision
to complete long term follow-up, our analysis goes some way
to address any dropout imbalances between intervention and
control groups.
The WSD telehealth interventions were complex,58 involving
both human services and advanced assistive technologies. A
number of issues were likely to arise in the economic evaluation
of such complex interventions: users might be a heterogeneous
group; users could be highly involved in the production of care;
the more active the user involvement, the more complicated the
association is between inputs and outputs; andmultiple agencies
could be involved in delivering the intervention.59 The
intervention involved coproduction by teams that varied in
composition from site to site.
Heterogeneity inevitably arose from differences in the way the
interventions were delivered. There also could have been
variations in the mix and balance of mainstream services within
and between health and social care providers in the sites.
Although use of the intervention at multiple sites improved
generalisability, it was more difficult to specify the intervention
to be used and identify which features might have been more
helpful in improving health related quality of life. The trial was
not intended nor powered to examine differences in outcomes
between specific service delivery models, although this could
be a secondary analysis. However, there were core features of
the telehealth intervention across sites: store and forward
systems, patient education protocols, computerised risk based
classification of vital signs data, and central monitoring teams.
Whether implementation of this “disruptive” technology60 at
these sites caused any system wide change in the delivery of
local health and social care services is beyond the scope of this
paper. However, other research in theWSD study has examined
the effects of telehealth on organisations and professionals.18
Our results focus on self reported outcomes and resource use,
and do not include surrogatemeasures of outcome such as levels
of glycated haemoglobin (HbA1c), blood pressure readings, or
mortality (although mortality is examined elsewhere).40 Recent
reviews and studies have identified promising results from trials
of telehealth in a variety of long term conditions including
diabetes, heart failure, chronic obstructive pulmonary disease,
and asthma. 8 9 13 15 61 62 However, the bulk of this evidence is
based on results measured by surrogate andmortality outcomes,
rather than by self reported data on health related quality of life.
Systematic reviews have reported mixed evidence in favour of
telehealth in terms of outcomes of health related quality of life
for people with diabetes8 and respiratory conditions.11 63 Evidence
has also favoured telemonitoring for people with coronary heart
failure,9 not least because of the diversity of generic and
condition specific measures reported.
It is also important to consider the country context when
comparing these results with previous studies, many of which
were US based. That healthcare is free at the point of use in the
UKmay mean that participants had better access to appropriate
primary care services than a comparable population of users in
the US; thus, there is less potential to reduce the use of the more
expensive services in secondary care. In this study, we noted a
non-significant reduction in secondary care costs in the
telehealth group. Another way in which the population might
have had less room to show improvement was in terms of the
level of need, or severity, of the index condition. Again, the
study was not designed or powered to examine the effectiveness
of telehealth within condition specific subgroups; however,
quality of life instruments for specific index conditions were
used, and are an area for further analysis.
One question arising from these results would be that the
timeframe of the evaluation may have been too short to show
improvements in health related quality of life, and is a potential
weakness shared with many published economic evaluations
of telemedicine.16 Similarly, there is no evidence base to show
that a longer time horizon leads to improved outcomes.
However, QALY gain could be modelled over an extended time
horizon, reflecting the different mortality rate between trial arms
identified in a concurrent study of the wider population in the
parent telehealth trial.47
This study raises some questions for further research: what is
the extent to which telehealth should be targeted towards specific
patient populations and subpopulations, and what is the
association between area level factors, patient characteristics
(demographics, needs levels for each index condition), and
variations in their service use and costs? We plan to examine
these associations in further analyses of the trial data.
There was a more extensive data collection involving unpaid
care, based on questionnaires completed by the carers of
respondents, as well as non-resource costs such as transfer
payments to respondents: an analysis of costs from a broader
societal perspective is planned using these data.
Comparison with other studies
Few telehealth evaluations have examined the association
between outcomes and costs.64 65 Recent reviews have found
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telehealth to be cost saving; however, the quality of the
evaluations reviewed has generally been described as poor.13 14 12
Some reviews have found telehealth to decrease use of acute
hospital services,8 9 11 but there is less evidence in terms of use
of primary care.8 Our study found a pattern of reduced use of
health and social care services by the telehealth group, if
intervention specific costs were excluded, although differences
were small.
Information on the costs of providing telehealth in the form of
telemonitoring has been scarce. Direct intervention costs of
telehealth (whether by telephone support or telemonitoring)
reported in the literature range widely, and come from a variety
of health systems and countries. Inglis and colleagues9 identified
a small number of studies of telemonitoring for heart failure
that gave such details. One66 noted that the costs of
telemonitoring increased the total costs for the intervention
group, but did not give the actual intervention cost; another67
provided a mean annual cost per patient for telemonitoring of
€185.9 Barlow and colleagues68 provided UK based estimates
of telehealth equipment costs of about £700-900 andmonitoring
costs of £260-520 per year (2007 prices). Estimated annual costs
of telehealth monitoring, support, and equipment in our study
varied between sites (about £1500-2000), reflecting the
heterogeneity in the models of telehealth delivery.
Because there are no societal thresholds for ICERs involving
ICECAP-O, Brief STAI, or CESD-10, we can only interpret
any positive findings related to these instruments with caution.
ICECAP-O is a relatively new instrument and little empirical
information currently exists on the average values expected in
a population with long term conditions, as well as on its use in
economic evaluations.69 70
Implications for clinicians and policymakers
Our results suggest that the QALY gain by people using
telehealth in addition to standard support and treatment was
similar to those receiving usual care, and that total costs for the
telehealth group were higher than for the usual care group. The
probability of cost effectiveness judged by reference to this
QALY measure was relatively low over a range of values of
willingness to pay. Total costs were sensitive to the costs of the
intervention, reducing the point estimate of the cost per QALY
substantially to about £12 000 (assuming that returns to scale
could be achievedwithout altering outcomes). However, because
the difference in total costs between treatment groups was not
significant even with these assumed reductions, the probability
of cost effectiveness was only about 61% at the £30 000
threshold of willingness to pay, used as a reference by NICE.
These results take into account costs to both health and social
care systems, to give a picture of the consequences to costs and
quality of life from investment in telehealth across the agencies.
If investment in telehealth falls mainly to primary and social
care purchasers, while most savings accrue to the acute
sector—for which there is some weak evidence here—then
reinvestment into community health and social care services
would be vital.
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Tables
Table 1| Self reported service use (contacts) and unit costs to be applied, across treatment groups at 12 month follow-up
UnitUnit cost (£)
Between group differenceMean (SE) contacts*
Service use item
Standardised
(%)†Raw (£)Telehealth (n=538)Usual care (n=431)
Hospital use
Per attendance26103.00-133.00−13.7−0.15‡0.23 (0.04)0.38 (0.07)Emergency department
Per day26116.00-1657.00−5.0−0.250.98 (0.22)1.23 (0.24)Inpatient bed days
Per attendance26156.00-1496.00−5.4−0.130.39 (0.1)0.51 (0.12)Day hospital and other day
attendances
Per attendance2623.00-306.00−8.3−0.181.07 (0.08)1.26 (0.13)Outpatient attendances
Community health services/primary care
Per visit24192.00−8.0−0.050.13 (0.02)0.18 (0.04)Paramedic
Per minute, per visit241.31, 38.00−1.9−0.060.7 (0.14)0.76 (0.15)Community matron (visit)
Per minute241.2810.40.180.38 (0.1)0.2 (0.04)Community matron (telephone)
Per minute,24 per visit241.13, 24.004.20.531.26 (0.74)0.73 (0.26)Community or district nurse
(visit)
Per minute240.526.80.100.24 (0.07)0.14 (0.06)Community or district nurse
(telephone)
Per minute240.52−9.3−0.241.26 (0.11)1.5 (0.15)Practice nurse
Per minute240.506.10.010.01 (0.01)0Night nurse
Per minute240.95-1.31−2.6−0.050.64 (0.08)0.69 (0.1)Specialist nurse
Per minute240.65−10.9−0.410.29 (0.08)0.7 (0.3)Physiotherapist or occupational
therapist
Per minute,24 per visit4.00, 94.00−11.1−0.100.23 (0.07)0.37 (0.07)GP (home)
Per minute, per visit242.40, 28.000.7−0.191.7 (0.1)1.69 (0.09)GP (surgery)
Per consultation2417.00−10.6−0.130.42 (0.04)0.52 (0.07)GP (telephone)
Contact2686.853.20.030.45 (0.05)0.42 (0.06)Dentist
Contact2635.37−0.4−0.010.6 (0.11)0.61 (0.13)Chiropodist
Per eye test2720.26−8.4−0.110.37 (0.04)0.48 (0.09)Optician
Community mental health
Per minute244.72−0.2−0.000.02 (0.01)0.02 (0.01)Psychiatrist
Per minute240.833.60.010.03 (0.02)0.02 (0.01)Mental health nurse
Community care services
Per minute240.92−6.0−0.190.16 (0.05)0.35 (0.23)Social worker
Per minute240.42−4.3−1.384.98 (1.5)6.36 (1.4)Day and evening care/help at
home
Per minute240.504.90.210.4 (0.24)0.19 (0.11)Paid night carer
Per meal245.002.30.200.65 (0.46)0.45 (0.26)Meals on wheels
Per adaptation241.50-4553.50.010.08 (0.02)0.07 (0.02)Major and minor adaptations
Per item24,28,290.20-97.52.20.020.19 (0.03)0.17 (0.04)Equipment (such as mobility,
ADL)
Care home respite
Per day2463.72-70.570.50.000.03 (0.03)0.02 (0.02)Days
Day services
Per attendance24,26 ,30, 3136.00-155.82−4.1−0.150.44 (0.16)0.59 (0.18)Day care and other day
attendances
Drug treatment
Various32Various1.70.078.64 (0.2)8.57 (0.23)No of drugs
£1=€1.14; $1.49. Unit costs were applied to the last three months before 12 month follow-up.
SE=standard error; ADL=activities of daily living.
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Table 1 (continued)
UnitUnit cost (£)
Between group differenceMean (SE) contacts*
Service use item
Standardised
(%)†Raw (£)Telehealth (n=538)Usual care (n=431)
*Mean contacts for all participants who completed the questionnaire within each treatment group.
†Standardised difference=difference between group means divided by standard deviation of the total sample.
‡P<0.05, t test.
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Table 2| Costs associated with self reported service use across treatment groups at 12 month follow-up
Between group differenceMean (SE) service costs (£)
Resource item Standardised (%)*Raw (£)Telehealth (n=538)Usual care (n=431)
−9.4−147.6518.7 (67.8)666.2 (74.9)Hospital costs
−8.0−33.3211 (17.1)244.2 (21.4)Primary care costs
0.50.21.7 (1.7)1.5 (1.5)Care home respite costs
−7.0−52.7140.3 (29.6)193 (39.6)Community care costs
−3.3−2.65.8 (2.6)8.4 (4.5)Mental healthcare costs
−6.3−14.528.2 (9.6)42.7 (11.4)Day care costs
0.60.12 (0.5)1.9 (0.6)Adaptations costs
3.00.10.5 (0.2)0.4 (0.2)Equipment costs
5.38.4230.4 (7.1)222 (7.4)Medication costs
Total costs
−11.6−241.81138.6 (88.6)1380.3 (102.4)Excluding telehealth delivery and equipment
9.9206.41596.1 (88.6)1389.7 (102.6)Including telehealth delivery and equipment
Telehealth
169.6164.6†168.5 (2.8)3.8 (1.4)Equipment costs
195.7283.6†289.1 (1.2)5.5 (1.9)Intervention costs
Sensitivity analyses
3.674.71461.3 (88.6)1386.6 (102.5)80% reduction in equipment prices
5.9124.11511.9 (88.6)1387.8 (102.5)50% reduction in equipment prices
4.390.11477.3 (88.6)1387.2 (102.5)Operating at increased capacity only
−2.0−41.61342.5 (88.6)1384.1 (102.4)Operating at increased capacity and 80% reduction in
equipment prices
0.47.81393.1 (88.6)1385.3 (102.5)Operating at increased capacity and 50% reduction in
equipment prices
£1=€1.14; $1.49. Costs apply to the last three months before 12 month follow-up. SE=standard error.
*Standardised difference=difference between group means divided by standard deviation of the total sample.
†P<0.01, t test.
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Table 3| Telehealth intervention costs (2009-10)
Range (£ per year)Cost category
338 598-540 381Inhouse staff*
188 249-490 748Computer hardware and peripherals
86 064-39 678Computer software
17 914-69 185Installation
8623-261 588Contract costs/fees to other organisations
840 464-1 168 671Total direct cost
1487-2042Total direct unit cost per participant
1134-1241Minus total equipment cost†
804-1199Minus posts/contracts specific to project management
580-733Assuming 1000 participants recruited per site‡
334-852Total equipment costs† per participant
£1=€1.14; $1.49. Costs were round to the nearest £1.
*Excludes costs of installation staff, which were reported separately.
†Total equipment costs=costs of base units and peripherals specific costs.
‡The monitoring costs of the service, assuming that it was functioning “at capacity” (for sensitivity analyses).
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Table 4| Baseline characteristics of participants with available baseline economic data, at baseline and 12 month follow-up
Participants not completing 12 month
follow-up
Participants completing 12month follow-up
study instrumentsTotal baseline sample
Difference
TH
(n=302)
UC
(n=297)
Difference
TH
(n=534)
UC
(n=431)
Difference
TH
(n=841)
UC
(n=728)
Stand
(%)*Raw (£)
Stand
(%)*Raw (£)
Stand
(%)*Raw (£)
−6.1−0.7870.5
(13.48)
71.3
(11.93)
−1.1−0.2170.0 (10.71)70.1
(11.66)
−4.0−0.4670.1 (11.8)70.6 (11.8)Age (years)
−4.1−2.041 (n=124)43 (n=162)8.13.841.6
(n=222)
37.6
(n=162)
2.91.441 (n=347)40 (n=290)Women (%)
4.90.7230.6
(15.75)
29.8
(13.91)
−12.0−1.6026.1 (14.3)27.7
(13.65)
−6.0−0.8727.7 (15)28.6 (13.8)IMD
(score)§¶
0.14.721.2 (n=64)16.5 (n=49)21.99.1‡28.2
(n=151)
18.9 (n=81)18.47.7‡26 (n=214)18 (n=130)Group 1
(%)§
−0.1−4.615.2 (n=46)19.9 (n=59)−16.9−6.8‡17.6 (n=94)24.5
(n=106)
−14.7−5.8‡17 (n=140)23 (n=199)Group 2
(%)§
0.12.417.5 (n=53)15.2 (n=45)1.50.619 (n=101)18.4 (n=79)3.71.418 (n=154)17 (n=180)Group 3
(%)§
−0.2−9.4‡17.9 (n=54)27.3 (n=81)0.50.120.4
(n=109)
20.2 (n=87)−8.8−3.719 (n=164)23 (n=196)Group 4
(%)§
0.26.9†28.1 (n=85)21.2 (n=63)−8.9−3.014.8 (n=79)18.1 (n=78)0.90.420 (n=166)19 (n=157)Group 5
(%)§**
Index condition (%)
−4.7−2.232.8 (n=99)35 (n=104)22.511.1‡43.4
(n=232)
32.5
(n=140)
12.86.1†39.7
(n=334)
33.5
(n=244)
COPD
−11.2−5.228.5 (n=86)33.7
(n=100)
−15.5−7.8†33.1
(n=177)
40.6
(n=175)
−13.7−6.5‡31.3
(n=263)
37.8
(n=275)
Heart failure
15.67.438.7
(n=117)
31.3 (n=93)−8.1−3.423.4
(n=125)
26.9
(n=116)
0.7−0.329 (n=244)28.7
(n=209)
Diabetes††
−4.9−0.092
(1.8)
2.1
(1.8)
−12.0−0.221.8
(1.8)
2
(1.9)
−9.7−0.181.8
(1.8)
2
(1.9)
No of
comorbidities
−10.7−1951341
(1751)
1536
(1875)
5.0921172 (1620)1096
(1408)
−1.9−321244
(1687)
1276
(1628)
Baseline
costs (£)
WSD site (%)
−7.5−7.5†26.8 (n=81)34.3
(n=102)
4.21.832.6
(n=174)
30.6
(n=132)−1.9
−1.730.4
(n=256)
32.1
(n=234)
Site 1
1.41.434.8
(n=105)
33.3 (n=99)3.01.344.2
(n=236)
42.7
(n=184)2.0
1.840.7
(n=342)
38.9
(n=283)
Site 2
6.16.138.4
(n=116)
32.3 (n=96)-8.0−3.123.2
(n=124)
26.7
(n=115)
−0.2−0.228.9
(n=243)
29 (n=211)Site 3‡‡
−1.6−1.680 (n=242)84.5
(n=251)
6.41.689.5
(n=477)
87.5
(n=377)
1.70.686.9
(n=730)
86.3
(n=628)
White British
ethnicity (%)§
£1=€1.14; $1.49. Data are mean (standard deviation) or proportion (%) and no of patients.
UC=usual care; TH=telehealth; Stand=standardised difference; COPD=chronic obstructive pulmonary disease.
*Standardised difference=difference between group means divided by standard deviation of the total sample.
†P<0.05 on z test of proportions.
‡P<0.01 on z test of proportions.
§Imputed data.
¶Difference between means of TH group sample at baseline and 12 month follow-up: P<0.05, t=2.09 (unpaired t test).
**Difference between proportions of patients in TH group at baseline and 12 month follow-up: z=2.34, P<0.05.
††Difference between proportions of patients in TH group at baseline and 12 month follow-up: z=2.29, P<0.05.
‡‡Difference between proportions of patients in TH group at baseline and 12 month follow-up: z=2.32, P<0.05.
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Table 5| Differences in costs* and effect between treatment groups at 12 month follow-up, from net benefit analyses. Data are mean (95%
confidence interval) unless otherwise stated
Between group difference
or ICER (95% CI)Telehealth (n=534)Usual care (n=431)
Primary outcome
0.012 (−0.026 to 0.049)0.564 (0.535 to 0.585)0.549 (0.52 to 0.577)QALY (raw mean difference)†
826 (−689 to 2340)6384 (5688 to 7081)5559 (4752 to 6366)Cost (£; raw mean difference)†
0.012——QALY (adjusted mean difference)§‡
1110 (−1 to 2220)6511 (5905 to 7116)5401 (4498 to 6305)Cost (£; adjusted mean difference)§
92 000 (0 to undefined)——ICER (£ per QALY)§¶
Costs excluding project management costs (£)
637 (−427 to 1702)6193 (5491 to 6895)5555 (4748 to 6362)Raw mean difference†
928 (−184 to 2040)6322 (5712 to 6933)5395 (4492 to 6297)Adjusted mean difference§
79 000 (undefined)——ICER (£ per QALY)§¶
Sensitivity analyses
Equipment prices reduced by 50%
779 (−333 to 1890)6174 (5566 to 6782)5395 (4492 to 6298)Cost (£; adjusted mean difference)§
68 000 (undefined)——ICER (£ per QALY)§¶
Equipment prices reduced by 80%
580 (−532 to 1693)5972 (5362 to 6582)5391 (4488 to 6295)Cost (£; adjusted mean difference)§
52 000 (undefined)——ICER (£ per QALY)§¶
Operating at increased capacity
639 (−471 to 1749)6034 (5430 to 6638)5395 (4491 to 6299)Cost (£; adjusted mean difference)§
57 000 (undefined)——ICER (£ per QALY)§¶
Operating at increased capacity and equipment prices reduced by 50%
308 (−803 to 1419)5697 (5090 to 6304)5389 (4486 to 6293)Cost (£; adjusted mean difference)§
31 000 (undefined)——ICER (£ per QALY)§¶
Operating at increased capacity and equipment prices reduced by 80%
109 (−1002 to 1221)5495 (4886 to 6104)5386 (4482 to 6289)Cost (£; adjusted mean difference)§
12 000 (undefined)——ICER (£ per QALY)§¶
Secondary outcomes
ICECAP-O
0.014 (−0.011 to 0.031)0.766 (0.75 to 0.781)0.751 (0.734 to 0.768)Raw mean difference†
0.012——Adjusted mean difference§‡
98 000 (8000 to undefined)——ICER (£)§¶
Brief STAI
−0.801 (−1.327 to −0.275)10.694 (10.347 to 11.04)11.495 (11.093 to 11.896)Raw mean difference†
−0.762——Adjusted mean difference§‡**
27 000 (1000 to 86 000)——ICER (£)§¶
CESD-10
−0.781 (−1.613 to 0.052)9.725 (9.17 to 10.281)10.506 (9.882 to 11.13)Raw mean difference†
−0.639——Adjusted mean difference§‡††
9000 (0 to 160 000)——ICER (£)§¶
£1=€1.14; $1.49.
*Annual equivalent costs.
†Cases for which costs data at baseline were available.
‡Derived from slope of net monetary benefit line.
§From net benefit analyses, data adjusted for baseline costs, baseline outcome, site, demographic covariates (age, sex, ethnicity, IMD, number of chronic conditions,
index condition).
¶Rounded to nearest 1000.
**Retransformed to original scale to enable comparison with raw mean difference; transformed mean=0.042.
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Table 5 (continued)
Between group difference
or ICER (95% CI)Telehealth (n=534)Usual care (n=431)
††Retransformed to original scale to enable comparison with raw mean difference; transformed mean=0.128.
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Figures
Fig 1 Cost effectiveness acceptability curve: QALY
Fig 2 Cost effectiveness acceptability curve: ICECAP-O
Fig 3 Cost effectiveness acceptability curve: Brief STAI
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Fig 4 Cost effectiveness acceptability curve: CESD-10
Fig 5 Cost effectiveness acceptability curve: QALY (sensitivity analyses). Full utilisation=service working to capacity
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